Forward P/S Multiple: PROCEPT BioRobotics Corporation (PRCT)
Ambitious management is driving rapid market capture for PROCEPT BioRobotics (PRCT), as confirmed by an upward trend where the current value equals 3.80. The forward P/S ratio reflects investor optimism. Growth is based on unique aquablation in the US and steady revenue from the sale of consumables for robotic consoles for urologists.
Summary analytical data breakdowns for Procept (PRCT)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital PROCEPT BioRobotics|PRCT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital PROCEPT BioRobotics|PRCT - Company Aggregate Debts|Debt to Book Capitalization Ratio Procept|PRCT - Company Long-Term Debt|Company Current Liabilities PROCEPT BioRobotics|Quick Ratio procept-biorobotics.com
- financial results and valuation multiples details:
PRCT - Company Net Income|Expected Profit PROCEPT BioRobotics|PRCT - Market Cap to Net Income Ratio|Projected Price to Earnings PROCEPT BioRobotics Inc|PRCT - PEG Multiple|EV/EBITDA Multiple Procept|PRCT - Operating income before deduction of amortization|Earnings per share for the last twelve months PROCEPT BioRobotics|PRCT - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months procept-biorobotics.com|PRCT - Net earnings per share growth this year|Earnings growth forecast for next year PROCEPT BioRobotics
- sales and revenue indicators:
Fundamental company analysis:PRCT (PROCEPT BioRobotics Corporation)
PROCEPT BioRobotics revenue is based on the sale of AquaBeam systems and consumables, making the forward P/S multiple a critical tool for assessing expected capitalization relative to future sales. The current value of 3.80 allows investors to filter out market noise and determine whether the revenue premium is justified given the global expansion rates of medical equipment.
Who PROCEPT BioRobotics competes with
Price-to-Projected Revenue Ratio Dexcom DXCM|PEN - Forward Price-to-Revenue Multiple|Novanta Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Haemonetics Company|INSP: Forward P/S Multiple|Market Cap to Projected Revenue CNMD|PLSE (Pulse Biosciences) - Forward P/S Multiple|InMode Ltd (INMD) - Market Cap to Expected Sales Ratio|Forward P/S Multiple PMI|Forward Price-to-Revenue Multiple Surmodics Inc. SRDX|Forward P/S Multiple SENS (Senseonics Holdings)|Forward P/S Multiple neuropace.com NPCE|TCMD - Price-to-Projected Revenue Ratio|SNWV: Price-to-Projected Revenue Ratio|OM (Outset) - Forward Price-to-Revenue Multiple|Electromed - Forward Price to Sales|LNSR (LENSAR, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio avitamedical.com RCEL|Price-to-Projected Revenue Ratio Profound Medical Corp. (PROF)|bairdmed.com (BDMD) - Projected Price to Revenue|EDAP TMS - Forward Price-to-Revenue Multiple|Forward P/S Multiple Apyx Medical Corp APYX|IceCure Medical, Ltd. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Pulmonx Corporation LUNG|telabio.com (TELA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CTSO (CytoSorbents Corporation)|Price-to-Projected Revenue Ratio Sensus Healthcare Corp|Forward Price-to-Revenue Multiple Zynex Corp (ZYXI)|Forward P/S Multiple ECOR|RBOT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Inspira Technologies IINN|ICU: Market Cap to Projected Revenue|IRIX: Forward Price-to-Revenue Multiple|Intelligent Bio Solutions - Price to Expected Revenue Ratio|beyondair.net (XAIR) - Price-to-Projected Revenue Ratio|Future Price to Revenue PFSA (profusa.com)|Price-to-Projected Revenue Ratio STRATA Skin Sciences Inc.|GCTK: Forward Price to Sales|Price-to-Projected Revenue Ratio NanoVibronix (NAOV)|VERO - Market Cap to Future Revenue Ratio|Forward P/S Multiple NUWE (Nuwellis, Inc.)|AEMD - Forward Price-to-Revenue Multiple|TransEnterix - Forward P/S Multiple|Market Cap to Future Revenue Ratio Avinger Inc.|BioSig Technologies, Inc (BSGM) - Price-to-Projected Revenue Ratio|Future Price to Revenue CUTR (Cutera Inc)|Forward Price-to-Revenue Multiple KNW|NARI (inarimedical.com) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple NVRO (Nevro)|RSLS (reshapelifesciences.com) - Forward Price to Sales|Forward P/S Multiple SILK (Silk Road Medical Inc.)
